Word wide incidence of prostate cancer increased last few decades as a result of early detection by core needle biopsy. Differentiation of prostate adenocarcinoma from benign prostate lesions and hyperplasia sometimes cannot be done on the sole basis of morphologic findings. Diagnosis of prostatic carcinoma on routine biopsies can be challenging when pathologists are faced with certain problems such as limited tissue sample, small foci of carcinoma, or benign mimics of prostate cancer like atrophy and atypical adenomatous hyperplasia, basal cell hyperplasia. In these cases, the diagnosis can be made according to the presence or absence of the basal cell layer, considering the fact that in the prostatic adenocarcinoma, there is no basal cell layer but benign lesions have encirclement by this layer. Hence, using basal cell immunohistochemistry markers including p63 and 34βE12 seems useful in distinguishing these two important categories of prostate lesions. Immunohistochemistry (IHC) is a valuable adjunctive in the diagnosis of minute foci of prostatic carcinoma and to differentiate it from benign mimickers and precursor lesions. Objective of this study is to find the usefulness of basal cell markers namely p63 and 34βE12 for diagnosis of adenocarcinoma and to differentiate them from cancer mimickers. Another objective of this study is to compare sensitivity and specificity of p63 and 34βE12 as immunomarker in distinguishing prostatic carcinoma from benign prostatic lesions.